Ferrochelatase Antibody (D-7): sc-271434

Ferrochelatase Antibody (D-7) is a mouse monoclonal IgG2b antibody that detects Ferrochelatase in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Ferrochelatase, also known as heme synthetase or protoheme ferro-lyase, plays a crucial role as the terminal enzyme in the biosynthesis of protoheme, catalyzing the insertion of ferrous iron into protoporphyrin IX. This enzymatic activity is vital for the production of heme, an essential component of hemoglobin and various cytochromes, which are critical for oxygen transport and cellular respiration. Ferrochelatase is primarily located in the mitochondria, where anti-Ferrochelatase antibody (D-7) shows association with the mitochondrial membrane, underscoring its importance in cellular energy metabolism. Ferrochelatase is a homodimeric protein that features two nitric oxide-sensitive clusters and coordinated 2FE-2S clusters, which may function as sensors for nitric oxide, linking heme biosynthesis to cellular signaling pathways. Mutations in the gene encoding Ferrochelatase, known as FECH, can lead to erythropoietic protoporphyria (EPP), a dominantly inherited disorder characterized by photosensitivity and hepatobiliary complications, highlighting the clinical significance of this protein. Ferrochelatase monoclonal antibody (D-7) is an invaluable tool for researchers studying heme metabolism and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ferrochelatase Antibody (D-7) References:

1. Substrate interactions with human ferrochelatase.  |  Medlock, A., et al. 2007. Proc Natl Acad Sci U S A. 104: 1789-93. PMID: 17261801
2. Ferrochelatase is a therapeutic target for ocular neovascularization.  |  Basavarajappa, HD., et al. 2017. EMBO Mol Med. 9: 786-801. PMID: 28377496
3. Ferrochelatase regulates retinal neovascularization.  |  Pran Babu, SPS., et al. 2020. FASEB J. 34: 12419-12435. PMID: 32716567
4. Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.  |  Sishtla, K., et al. 2022. Cell Chem Biol. 29: 1010-1023.e14. PMID: 35090600
5. Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria.  |  Obi, CD., et al. 2022. Front Cell Dev Biol. 10: 894591. PMID: 35646904
6. Proteomic Analysis of Ferrochelatase Interactome in Erythroid and Non-Erythroid Cells.  |  Obi, CD., et al. 2023. Life (Basel). 13: PMID: 36836934
7. Glutamate dehydrogenase combined with ferrochelatase as a biomarker of liver injury induced by antituberculosis drugs.  |  He, B., et al. 2023. Br J Clin Pharmacol. 89: 3092-3104. PMID: 37259680
8. Iron insertion into coproporphyrin III-ferrochelatase complex: Evidence for an intermediate distorted catalytic species.  |  Gabler, T., et al. 2023. Protein Sci. 32: e4788. PMID: 37743577
9. Structure and function of ferrochelatase.  |  Ferreira, GC., et al. 1995. J Bioenerg Biomembr. 27: 221-9. PMID: 7592569
10. Molecular and genetic characterization of ferrochelatase.  |  Taketani, S. 1993. Tohoku J Exp Med. 171: 1-20. PMID: 8122254

The preferred Ferrochelatase antibody is Ferrochelatase Antibody (A-3): sc-377377.